Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: J Immunol. 2020 Jul 13;205(5):1406–1418. doi: 10.4049/jimmunol.1901112

FIGURE 15.

FIGURE 15.

MDMs from rs1517352 CC disease risk carriers demonstrate increased intracellular bacterial clearance relative to AA carrier MDMs. Human MDMs from rs1517352 CC, CA, and AA carriers (n = 10 per genotype) were left untreated or treated for 48 h with 0.1 μg/ml lipid A. (A) ROS production. (B) NOS2 expression. (C) LC3II expression. Representative flow cytometry and summary graphs (mean fluorescence intensity [MFI]). (D) Intracellular bacterial clearance (CFU). Mean + SEM. Significance with one-way ANOVA with Tukey posttest. *p < 0.05, **p < 0.01, ***p < 0.001, †p < 1 × 10−4, ††p < 1 × 10−5. NT, no treatment; Tx, treatment.